Q-omics provides the consensus-scored GPR174 profile across patient tissues and cancer cell-line models. GPR174 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, GPR174 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, GPR174 RNA expression shows 18,368 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight SKCM, KIRC, and DLBC as cancer lineages where GPR174 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR174 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR174 survival associations across molecular data types. GPR174 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR174 RNA expression–survival associations across cancer types. High GPR174 expression shows unfavorable associations in LGG and UVM, but favorable associations in SKCM, HNSC, LUAD and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for GPR174 RNA expression.
This table summarizes GPR174 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR174. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR174 shows lower tumor expression in COAD, THCA and LUSC and higher tumor expression in KIRC, STAD and LUAD. The KIRC box plot shows higher GPR174 RNA expression in tumor versus normal tissue (log2 FC = +1.405, t-test p < 0.001).
This table shows molecular features associated with GPR174 in patient tissues and cancer cell lines. In patient samples, GPR174 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR174 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
